9/08/10
FirstString Research Release
CHARLESTON, S.C. – September 8, 2010 – FirstString Research, a biotechnology company focused on the development and commercialization of its therapeutic platform for wound healing, scar reduction and tissue regeneration, announced a major milestone in its development with the completion of Phase I clinical trials. “This trial, in 48 human subjects, has successfully demonstrated the safety and early efficacy of our compound,” said FirstString Chief Executive, Dr. Gautam Ghatnekar.
FirstString Research has raised additional capital needed to complete the successive Phase II trial. “We expect to get a larger Phase II trial underway shortly to further demonstrate the efficacy and safety of our lead compound,” said Dr. Ghatnekar.
FirstString has also received patents from the United States Patent and Trademark Office (USPTO) on its composition of matter claims – effectively giving the company a concrete asset by validating their core technology platform. On the subject of its technology, Dr Ghatnekar stated that the company’s patent portfolio is broad and extensive, and the company expects to have additional patents issued shortly.
About FirstString Research, Inc.
FirstString is a biotechnology company focused on the development and commercialization of therapeutics for wound healing, scar reduction and tissue regeneration. FirstString's proprietary therapies modulate intercellular communication to significantly reduce the development of scar tissue and, at the same time, improve the body's ability to produce healthy, functional cells. For further information, please visit www.firststringresearch.com.
###
Media Contact:
Dr. Gautam Ghatnekar
Phone: 843.860.8372
Fax: 843.720.3835
return to list
print
forward to friend
submit news